Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
253 results about "AIDS disorders" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
ActiveUS20080220092A1Improve performanceReduce the amount requiredHeavy metal active ingredientsBiocidePhytochemicalAntioxidant
Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.
Owner:MORNINGSIDE VENTURE INVESTMENTS
Methods for modulating macrophage proliferation using polyamine analogs
Owner:RGT UNIV OF CALIFORNIA
Method for treating cachexia with retinoid ligands
InactiveUS20070185055A1BiocideSilicon compound active ingredientsRetinoidObstructive Pulmonary Diseases
The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.
Owner:JIANG GUANG LIANG +2
Pharmacological agent and method of treatment
InactiveUS20060074063A1Eliminate effectiveEliminate energyBiocideGroup 8/9/10/18 element organic compoundsWhole bodyVirus warts
An antiproliferative, antiinflammatory, antiinfective, immunization agent of a metal ion chelating agent such as picolinic acid, analogs or derivatives thereof, and methods of using the same. The agents chelate metals in metal containing protein complexes and enzymes required for growth, replication or inflammatory response. The preparations can be administered systemically or topically. The products can be used to reduce systemic levels of metals in disease states such as Wilson's disease, iron or lead toxicity. The preparations have antineoplastic, antiviral, antiinflammatory, analgesic antiangiogenic and antiproliferative effects and are used in the treatment of warts, psoriasis, acne, cancers, sunburn, inflammatory responses, untoward angiogenesis and other diseases and in the prevention of sexually transmitted diseases such as genital warts, herpes and AIDS.
Owner:NOVACTYL
Methods of treating HIV infection
Owner:VIIV HEALTHCARE UK (NO 5) LTD
Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
InactiveUS20080214512A1Significant positive effectEndometriosis can be reducedOrganic active ingredientsBiocideSide effectBone density
The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that required to inhibit ovulation together with one or more pharmaceutical aids and / or carriers. The daily dose units are administered in a method of prophylaxis and / or therapy of endometriosis continuously during a time interval of at least 169 days or 25 weeks, preferably more than two years. The method effectively reduces endometriosis and associated pain, while undesirable side effects including bone density decrease are reduced or eliminated.
Owner:BAYER SCHERING PHARMA AG
Medicine composition for treating fatigue syndrome of sub-healthy people and hypodynamia and inferior immunologic function of patient with acquired immune deficiency syndrome and preparation method thereof
InactiveCN101711833AImprove immunityImprove self-healing abilityAntinoxious agentsUnknown materialsImmunologic functionImmune deficiency syndrome
The invention discloses a novel traditional Chinese medicine composition for treating the fatigue syndrome of sub-healthy people and the fatigue, the hypodynamia and the inferior immunologic function of a patient with acquired immune deficiency syndrome and a preparation method thereof. The main components of the traditional Chinese medicine composition comprise the following several raw materials of medicines: crude astragalus root, yam, white peony root, radix codonopsis pilosulae, angelica, solomonseal, ginseng, tuber fleeceflower, American ginseng, antler, aweto, ophiopogon root, Chinese wolfberry and prepared rehmannia root. The medicine composition can be prepared into any common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can obviously improve sub-health, fatigue syndrome, fatigue and hypodynamia of patients with acquired immune deficiency syndrome, enhances the self immunity and has the advantages of definite curative effect, obvious effect, convenient taking, quick acting, wide suitable crowd, no toxic or side effect and the like.
Owner:TAIYI HEPU BEIJING RES INST OF TCM
Methods for modulating macrophage proliferation using polyamine analogs
Methods for modulating macrophage proliferation in an individual afflicted with or at risk for a macrophage-associated disease are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including AIDS (HIV)-associated dementia, AIDS-associated non-Hodgkin's lymphoma, and Alzheimer's disease. The invention also provides methods for aiding diagnosis and monitoring therapy of a macrophage-associated non-HIV associated dementia, especially Alzheimer's disease. The invention also provides methods of delaying development of macrophage-associated non-HIV associated dementias, including Alzheimer's disease, which entail administration of an agent which modulates macrophage proliferation.
Owner:RGT UNIV OF CALIFORNIA
Application of berberine and derivatives thereof in preparation of indole amine 2, 3-dioxygenase inhibitor
The invention relates to novel application of berberine and derivatives thereof in preparation of medicines, in particular to application of berberine and derivatives thereof in preparation of indole amine 2, 3-dioxygenase IDO inhibitor, belonging to the medicine field. According to IDO inhibition activity detection, reversible inhibition judgment, inhibitor type judgment, Ki value determination and median effective inhibition concentration IC50 determination, the results show that berberine is reversible inhibitor and inhibition constant Ki is 8muM; and jatrorrhizine hydrochloride and palmatine hydrochloride are irreversible inhibitors, and the median effective inhibition concentrations IC50 thereof are respectively 123muM and 126muM. When the berberine and the derivatives thereof disclosed in the invention are used as IDO inhibitors, the application prospect is wide and the IDO inhibitors can be used for treating serious diseases such as cancers, AIDS, Alzheimer diseases, tristimania, cataract and the like with pathological feature of IDO-mediated tryptophan metabolism.
Owner:FUDAN UNIV
Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency
InactiveUS20100166806A1Adverse propertyPrevent HIV-1-induced cytotoxicityBiocideOrganic chemistryReverse transcriptaseHydroxamic acid
The invention relates to a combination of treatments, more particularly a combination treatment for HIV-1 infection. The present invention is directed to the use of bryostatin-1 and their natural and synthetic derivatives for AIDS therapy, in particular to the use of bryostatins in combination with other active drugs such as Histone Deacetylases (HDACs) inhibitors and anti-retrovirals, for the treatment of HIV-1 latency. According to the present invention, we provide a combination therapy for the treatment of HIV-1 latency which employs bryostatin-1 (and analogues) and one of the following HDAC inhibitors; valproic acid, butyrate derivatives, hydroxamic acids and benzamides. While HDACi can be used in continuous dosing protocol, bryostatins can be used following a cyclical dosing protocol. Bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles, phospholipids nanosomes and / or biodegradable polymer nanospheres. This combination therapy needs to be used in patients treated with antiretroviral therapy (HIV-1 protease inhibitors, HIV-1 reverse transcriptase inhibitors, HIV-1 integrase inhibitors, CCR5 co-receptor inhibitors and fusion inhibitors).
Owner:APHIOS
Novel production process of tenofovir
InactiveCN102219805ANo pollution in the processLow costGroup 5/15 element organic compoundsDimethyl methylphosphonateHydrolysis
The invention relates to a production process of drug tenofovir in the field of aids treatment. The process is a method of using adenine as a raw material, condensing toluenesulfonyloxy dimethyl methyl phosphonate by using an intermediate and then hydrolyzing by using an inorganic acid to finally prepare the tenofovir. The production process of the drug tenofovir, provided by the invention, has the characteristic of improving the hydrolysis activity of the intermediate so that the operation of the process production is largely simplified and the production cost of the tenofovir is largely reduced.
Owner:SUZHOU TENGLONG BIO PHARMA TECH
Polyamine micromolecular developer, production method and application thereof
InactiveCN102442996AReduce intakeExcellent treatment monitoringOrganic chemistryIn-vivo radioactive preparationsAlkaneApoptosis
The invention relates to a polyamine micromolecular compound, comprising the following structures described in the specification, wherein M<x+> is 0, Zn<2+>, Ga<3+>, Gd<3+>, Ca<2+> or other divalent metal ions and trivalent metal ions; S is a reporter group (including a nuclide labeling prothetic group, a paramagnet, a fluorescein or a microvesicle), such as the nuclide labeling prothetic group: -<11>CH3, -CH2CH2<18>F, -CH2CH2(OCH2CH2)2NHCOC6H4<18>F-p or -CH2CH2(OCH2CH2)2NH-CH2CH2<18>F; R is -H, -OCH3, -OCH2CH3 or -Cl; and R1, R2, R3 and R4 are hydrogen, carboxyl, alkane, alkylene or heteroalkyl. The invention further relates to application of the compound in preparing cell death or apoptosis developers of target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>. The compound provided by the invention is a specific multiamine micromolecular developer for target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>, which can be used for monitoring curative effects of PS-related anti-tumor chemotherapy, radiotherapy, biological therapy and the like; the compound can be used for early differential diagnosis of neurodegenerative diseases (senile dementia and Parkinson's disease), cerebral apoplexy, AIDS (Acquired immune deficiency syndrome), thrombus, atheromatous plaque and myocardial infarction; and the compound can also be used for differential diagnosis and curative effect monitoring of other diseases related to PS expression in the cell death or apoptosis process, such as inflammation development and anti-inflammation therapeutic development.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Systemic Treatment of Pathological Conditions Resulting From Oxidative Stress and/or Redox Imbalance
Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and / or thiosulfate compounds and / or thionite compounds and / or sulfite compounds and / or thionate compounds and / or any organic, inorganic or organometallic precursors thereof. The unique compositions of this invention contain one or more “active sulfur compounds” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic compounds.
Owner:SULFAGENIX
Utilization of Wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
InactiveUS6251388B1Highly efficaciousLess immunosuppressive activitySugar derivativesBacteriaHomotetramerAutoimmune condition
Described herein are methods for producing recombinant forms of asparaginase derived from Wolinella succinogenes. In addition, methods for covalent modification of proteins, including asparaginases, by acylation are also provided. Certain embodiments provide for epitopic-labeling of the amino terminus of W. succinogenes asparaginase. Additional embodiments concern methods for the therapeutic utilization of the native, homotetrameric form of W. succinogenes asparaginase, as well as the use of epitopically-labeled or non-epitopically-labeled recombinant W. succinogenes asparaginase (or a covalently modified analog thereof) in the therapeutic treatment of malignant and non-malignant hematological disease and other diseases where asparagine depletion or deprivation would be efficacious or which respond to asparagine depletion or deprivation, as well as their potential utilization in the therapeutic treatment of autoimmune diseases such as rheumatoid arthritis, AIDS, and SLE.
Owner:CHILDRENS HOSPITAL OF LOS ANGELES
Treatment of HIV and aids using probiotic lactobacillus reuteri
InactiveUS20100143305A1Reducing and preventing depletionReducing and preventing HIV replicationBiocidePeptide/protein ingredientsImmunodeficiency virusHuman immunodeficiency
A method for treating or preventing a Human Immunodeficiency Virus (HIV) infection, or treating or preventing Acquired Human Immunodeficiency Syndrome (AIDS), in a subject in need thereof, is disclosed. The method involves colonizing a genetically modified probiotic Lactobacillus reuteri RC-14 in the gastrointestinal tract of a subject, wherein the probiotic is able to secrete two or more fusion inhibitors that decrease or prevent HIV production and CD4+T cell depletion in the gastrointestinal tract.
Owner:LEMKE JAMES ALLEN
Universal unisex safety condom
InactiveUS20060278236A1High safety standardsCreate ease of useMale contraceptivesFemale contraceptivesPenisMale gender
This invention relates to the field of contraception and to the control of venereal disease transmission, including AIDS and HIV infection. The invention is a method of making an improved condom which can be used by either a male or by a female partner and can be inserted into a sexual orifice without first rolling it over an erect penis.
Owner:RESNIC DANIEL
Method of screening for modulators of HIV infection
The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.
Owner:OGEDA SA
USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS
This application provides a method for the use of select quaternary ammonium antagonists to alpha-7 nAChR for the treatment of cancer and HIV and AIDS.
Owner:UNIV OF KENTUCKY RES FOUND
Inhibition of gene expression using RNA interfering agents
Owner:IMMUNE DISEASE INST INC
Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate α4β2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.
Owner:NEUROPROTECTION FOR LIFE CORP
Inosine derivatives and production methods therefor
The present invention provides a method for producing an inosine derivative represented by the following general formula (1) including the steps of subjecting an inosine derivative of general formula (3) to dithiocarbonylation and carrying out radical reduction of the obtained compound. According to the present invention there can be produced compounds useful as anti-AIDS drugs on industrial scale. wherein R1 may be the same or different and are each benzyl group, benzhydryl group or trityl group, each of which may have a substituent in general formulas (1) and (3).
Owner:AJINOMOTO CO INC
Method of utilization of zygosaccharomyces rouxii
The present invention provides commercial utilization of a novel yeast strain Zygosaccharomyces rouxii and its fermented metabolites as probiotic, as an antioxidant and as an antimicrobial agent in foods and cosmetics. The fermented broth and metabolite substance (s) produced by this invention have a wide spectrum antibacterial activity, strong antioxidant activity, cytochalasin-like activity that inhibits cell cleavage, and is expected to be effective in the treatment of allergy, atopic dermatitis, psoriasis and various skin diseases, second degree burns, high blood pressure, diabetes, cancer, AIDS and as an anti-aging agent. Moreover, this invention is expected to lead to industrial utilization of Z.rouxii for manufacturing succinic acid and malic acid from a yeast.
Owner:OK TAING
Compositions and Methods for Treating Anemia
ActiveUS20180092892A1Reduced average total daily doseOrganic chemistryAmide active ingredientsRegimenNon dialysis dependent
Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
Owner:AKEBIA THERAPEUTICS
Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders
The present invention provides conformationally-defined macrocyclic compounds that bind to and / or are functional modulators of the motilin receptor including subtypes, isoforms and / or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and / or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.
Owner:OCERA THERAPEUTICS INC
Treatment of AIDS
InactiveUS20060194212A1Peptide/protein ingredientsMicrobiological testing/measurementTherapy HIVAntiretroviral therapy
The invention includes methods of treating HIV infection in a patient where the method includes administration of an antibody to TNF-alpha and an antibody to interferon-gamma to the patient and administering antiretroviral therapy to a patient. The invention further includes methods of treating HIV infection in a patient where the method comprises administration of an antibody to TNF-alpha and an antibody to alpha interferon to the patient and administering antiretroviral therapy to a patient. The invention further includes a method of treating HIV infection in a patient where the method includes administering an antibody to alpha interferon and antiretroviral therapy to a patient. The invention further includes a method of treating an HIV infection in a patient where the method comprises administering a chimeric TNF-alpha receptor and anti-retroviral therapy to a patient.
Owner:ADVANCED BIOTHERAPY
Therapeutic compounds
Compounds of formula I′:or salts thereof are provided. Pharmaceutical compositions comprising a compound of formula I′, processes for preparing compounds of formula I′, intermediates useful for preparing compounds of formula I′ and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal are also provided.
Owner:GILEAD SCI INC
Method and apparatus for infrared sterilization
InactiveUS6863864B1Less energyAvoid the needMaterial analysis using wave/particle radiationElectric discharge tubesEscherichia coliEating Utensils
The disclosed invention relates to sterilization by infrared radiation to eliminate pathogenic bacteria such as Salmonella, E. Coli 0157:H7 and E. Coli (EXEC) from articles such as medical, dental and veterinary instruments, as well as from tableware and eating utensils. The invention further relates to sterilization of soil, military and agriculture equipment to eliminate pathogenic bacteria such as hepatitis, AIDS, and anthrax, and prions such as mad cow disease using infrared radiation. Sterilization is performed by exposing the article to infrared radiation generated from heating elements positioned in an enclosed chamber.
Owner:U S STERILIZER CORP
Sulphatization derivative of polysaccharide, its preparation method and use
InactiveCN1651466ASignificantly anticoagulantAnti-platelet aggregation is goodOrganic active ingredientsImmunological disordersAntithrombotic AgentDisease
A polyose (YCP) sulfate derivative used for preparing anticoagulant, antithrombolic, antioxidizing medicine, antineoplastic medicine and anti-AIDS disease, and its preparing process are disclosed.
Owner:CHINA PHARM UNIV
Medicine for treating AIDS
The invention discloses a medicine for treating AIDS, and relates to a traditional Chinese medicine. The medicine is characterized by being made from the following raw materials: 15-25g of angelica, 25-35g of astragalus root, 25-35g of morinda root, 15-25g of red sage root and 1-15g of cassia. The following bulk drugs can also be added: spatholobus stem, pepper, largehead atractylodes, achyranthes root, black bean, pilose asiabell root, sheep manure, clematis root, dried ginger, fibrous root of fistular onion, fly larval and the like. The medicine is prepared by the following steps: taking the raw materials, soaking for 30-40m, adding 700-1000g of water, decocting with slow fire for 15-25m after boiling, and separating dregs from the decoction for oral administration; and baking and grinding the dregs into powder for oral administration. The medicine has the efficacies of invigorating spleen and stomach, invigorating vital energy and producing saliva, recuperating internal organs, nourishing blood and liver, promoting blood circulation to clear channels, enriching the blood and strengthening the bone, and killing viruses. The medicine is used for treating AIDS and has the curative ratio up to 97.7%, and can be also widely applied to treating diseases such as leukemia, aplastic anemia, thrombocytopenia, hepatitis, dermatosis and the like.
Owner:常俊平
1, 2, 3-triazole compound and application thereof in preparing indoleamine 2, 3-dioxygenase inhibitor
InactiveCN101786993APromote decompositionLow toxicitySenses disorderNervous disorderDiseaseTryptophan
The invention belongs to the field of pharmaceutical chemistry and relates to a 1, 2, 3-triazole compound, comprising 4-(2-bromophenyl)-1H-1, 2, 3-triazole and 4-(2-chlorphenyl)-1H-1, 2, 3-triazole. The result of an inhibitory activity test of indoleamine 2, 3-dioxygenase indicates that the disclosed 1, 2, 3-triazole compound used as the indoleamine 2, 3-dioxygenase inhibitor has broad prospect of application and can be applied to the treatment of diseases with indoleamine 2, 3-dioxygenase-mediated tryptophan metabolic pathway pathological characteristics, including cancer, AIDS (Acquired Immure Deficiency Syndrome), Alzheimer disease, tristimania, cataract and other critical diseases.
Owner:FUDAN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com